|
Dec 6, 2017 |
REDWOOD CITY, Calif., Dec. 6, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced a multi-year research collaboration agreement with Janssen Pharmaceuticals to evaluate the Oncotype DX Genomic Prostate Score™ (GPS™) test for their prostate cancer drug pipeline. As part of the agreement, Genomic Health will test sam...
|
|
|
Nov 30, 2017 |
REDWOOD CITY, Calif., Nov. 30, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present 10 Oncotype DX® studies at the 40th San Antonio Breast Cancer Symposium (SABCS), which is being held December 5-9, 2017. Presentation highlights include:
Positive results from an international validation study...
|
|
|
Nov 28, 2017 |
REDWOOD CITY, Calif. and CLEVELAND, Nov. 28, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX), the world's leading provider of genomic-based diagnostic tests, and Cleveland Diagnostics, Inc., a biotechnology company focused on developing next-generation diagnostics technology for the detection of cancers, today announced an exclusive licens...
|
|
|
Nov 21, 2017 |
REDWOOD CITY, Calif., Nov. 21, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 29th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, November 28, 2017 at 10:30 a.m. Eastern Time.
To access the live and subsequently archived webcast of the presentation, go to the Inve...
|
|
|
Nov 8, 2017 |
REDWOOD CITY, Calif., Nov. 8, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended September 30, 2017.
Total revenue was $83.8 million in the third quarter of 2017, compared with $82.3 million in the third quarter of 2016, an increase of 2 percent. Revenue was n...
|
|
|
Nov 1, 2017 |
REDWOOD CITY, Calif., Nov. 1, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, November 8 at 4:30 p.m. Eastern Time to discuss its third quarter 2017 financial results. The call and webcast will follow the release of the third quarter financial results af...
|
|
|
Sep 13, 2017 |
REDWOOD CITY, Calif. and MECHELEN, Belgium, Sept. 13, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests and Biocartis Group NV (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced an exclusive agreement to develop an in vitro diagnostic (IVD)...
|
|
|
Sep 11, 2017 |
REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of new data that provide additional evidence of the unmatched value of the Oncotype DX Breast Recurrence Score® test in accurately predicting outcomes in early-stage breast cancer patients. The data were presented at the 20...
|
|
|
Aug 31, 2017 |
REDWOOD CITY, Calif., Aug. 31, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from four Oncotype DX Breast Recurrence Score® test studies at the European Society for Medical Oncology (ESMO) 2017 Congress. The conference takes place September 8-12 at the IFEMA, Feria de Madrid, in ...
|
|
|
Aug 30, 2017 |
REDWOOD CITY, Calif., Aug. 30, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 2017 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6, 2017 at 9:05 a.m. Eastern Time.
To access the live and subsequently archived webcast of the presentation, go to the Investor Relations ...
|
|
